Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its
prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1
inhibitor have clinical benefits for OCCC patients. And the combination of bevacizumab and
PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims
to investigate the potential benefit of combination therapy for patients with OCCC.
Phase:
Phase 2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Anhui Provincial Cancer Hospital Henan Cancer Hospital Hubei Cancer Hospital Jingzhou Central Hospital Qilu Hospital of Shandong University Shengjing Hospital The First Affiliated Hospital of Zhengzhou University The First People's Hospital of Jingzhou Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan University Xiangyang Central Hospital